Mikael C.
- Country
- France
- Department
- Department of Neurology
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Randomized open-label trial comparing 2-month versus 6-month schedules of adjuvanted recombinant VZV glycoprotein E vaccine in MS and NMOSD patients on anti‑CD20 therapy
- A RANDOMIZED DOUBLE BLIND, PLACEBO-CONTROLLED NATIONAL MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY OF AZATHIOPRINE FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY ASSOCIATED DISEASE (MOG-AD) AFTER A FIRST ATTACK : MOGWAI
Data & Insights
Has run more than one trial at 60 of 212 partner sites.
Specializations
Multiple Sclerosis Management
The investigator specializes in advancing treatment approaches for relapsing-remitting multiple sclerosis (RRMS), with particular focus on therapeutic optimization and long-term disease management strategies.
- Anti-CD20 therapy evaluation
- Treatment de-escalation protocols
- Age-specific treatment considerations
Research encompasses innovative treatment schedules and maintenance strategies for MS patients across different age groups.
Neurological Immunotherapy
Focused on investigating novel therapeutic approaches in neuroimmunological conditions, particularly examining the efficacy of immunosuppressive treatments in autoimmune neurological disorders.
- Myelin oligodendrocyte glycoprotein antibody disorders
- Immunosuppressive therapy optimization
- Relapse prevention strategies
Investigates preventive approaches for autoimmune neurological conditions with emphasis on long-term disease control.
Treatment Optimization Studies
Conducts research on radiological disease activity assessment and treatment modification strategies in neurological conditions, focusing on personalized medicine approaches.
- Infusion protocol optimization
- Disease activity monitoring
- Long-term treatment outcomes
Evaluates innovative treatment schedules and their impact on disease progression and patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.